Table 1.

Summary of the experimental outcomes

Parameter	Sacubitril and Valsartan	Sacubitril	Valsartan
Driven by drug combination
Proteinuria	↓, P = 0.061	↔	↔
Renal medullary fibrosis	↓, P = 0.013*	↔	↓, P = 0.08
Primarily sacubitril driven
Atrial natriuretic peptide level in heart tissue	↑, P = 0.012*	↑, P = 0.000003*	↔
Glomerular filtration rate	↑, P = 0.002*	↑, P = 0.017*	↔
Primarily valsartan driven
Urinary kidney injury molecule-1 excretion	↓, P = 0.08	↔	↓, P = 0.02*
Systolic blood pressure	↔	↔	↓, P = 0.008*
Renal protein casts	↓, P = 0.003*	↔	↓, P = 0.009*
Both sacubitril and valsartan driven
Urinary neutrophil gelatinase-associated lipocalin excretion	↓, P = 0.00003*	↓, P = 0.002*	↓, P = 0.0002*
Creatinine excretion	↑, P = 0.001*	↑, P = 0.0004*	↑, P = 0.000073*

Shown is a summary of significant outcomes of the study driven by sacubitril only, valsartan only, both sacubitril and valsartan, and their combination. Outcomes with P < 0.05 and important outcomes with P > 0.05 (due to lower power) are shown. An increase, decrease, and no change (vs. the vehicle-treated group) are denoted as ↑, ↓, and ↔, respectively.

^*P < 0.05, outcome vs. vehicle (end point, on high-salt diet).